
AJUNTAMENT D'ALCOI
Website

Generalitat Valenciana
Website

Ayuntamiento de Valencia
Website

Cicloplast
Website

Ayuntamiento de Onil
Website

Anarpla
Website

Ayuntamiento de Mislata
Website

nlWA, North London Waste Authority
Website

Ayuntamiento de Salinas
Website

Zicla
Website

Fondazione Ecosistemi
Website

PEFC
Website

ALQUIENVAS
Website

DIPUTACI� DE VAL�NCIA
Website

AYUNTAMIENTO DE REQUENA
Website

UNIVERSIDAD DE ZARAGOZA
Website

OBSERVATORIO CONTRATACIÓN PÚBLICA
Website

AYUNTAMIENTO DE PAIPORTA
Website

AYUNTAMIENTO DE CUENCA
Website

BERL� S.A.
Website

CM PLASTIK
Website

TRANSFORMADORES INDUSTRIALES ECOL�GICOS

INDUSTRIAS AGAPITO
Website

RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
Ultra-high FRET efficiency NaGdF4: Tb3+-Rose Bengal biocompatible nanocomposite for X-ray excited photodynamic therapy application
The limitation of light penetration depth invalidates the application of photodynamic therapy in deep-seated tumors. X-ray excited photodynamic therapy (X-PDT), which is based on X-rays excited luminescent nanoparticles (XLNP), provides a new strategy for PDT in deep tissues. However, the high X-ray dosage used and non-specific cytotoxicity of the nanoparticle-photosensitizer nanocomposite (NPs-PS) hamper in-vivo X-PDT applications. To address these problems, a simple and efficient NPs-PS nanocomposite using ?-NaGdF4: Tb3+ nanoparticles and widely used PS called Rose Bengal (RB) was designed. With perfectly matched spectrum of NPs emission and RB absorption upon X-ray excitation and covalent conjugation of a large amount of RB on NP surfaces to minimize the energy transfer distance, the system demonstrated ultra-high FRET efficiency up to 99.739%, which leads to maximum production of singlet oxygen for PDT with significantly increased anti-tumor efficacy. By 2-aminoethylphosphonic acid surface modification of NPs, excellent biocompatibility was achieved even at a high concentration of 1?mg/mL. The in-vivo X-PDT efficacy was found around 90% of HepG2 tumor growth inhibition with X-ray dose of only 1.5?Gy, which shows the best anti-tumor efficacy at same X-ray dose level reported so far. The present work provides a promising platform for in-vivo X-PDT in deep tumors.

» Author: Wenli Zhang, Xiaofeng Zhang, Yingli Shen, Feng Shi, Chaojun Song, Tianshuai Liu, Peng Gao, Bin Lan, Miao Liu, Sicheng Wang, Li Fan, Hongbing Lu
» Reference: 10.1016/j.biomaterials.2018.09.001
» Publication Date: 01/11/2018
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es
